Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
KITE-222 by Gilead Sciences for Burkitt Lymphoma: Likelihood of Approval
KITE-222 is under clinical development by Gilead Sciences and currently in Phase II for Burkitt Lymphoma. According to GlobalData, Phase...
KITE-222 by Gilead Sciences for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
KITE-222 is under clinical development by Gilead Sciences and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL). According...
KITE-222 by Gilead Sciences for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
KITE-222 is under clinical development by Gilead Sciences and currently in Phase II for Primary Mediastinal B-Cell Lymphoma. According to...
KITE-222 by Gilead Sciences for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
KITE-222 is under clinical development by Gilead Sciences and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic...
KITE-222 by Gilead Sciences for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
KITE-222 is under clinical development by Gilead Sciences and currently in Phase II for Chronic Lymphocytic Leukemia (CLL). According to...
KITE-222 by Gilead Sciences for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
KITE-222 is under clinical development by Gilead Sciences and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to...
KITE-222 by Gilead Sciences for Mantle Cell Lymphoma: Likelihood of Approval
KITE-222 is under clinical development by Gilead Sciences and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Gilead Sciences's KITE-222?
KITE-222 is a gene-modified cell therapy commercialized by Gilead Sciences, with a leading Phase II program in Primary Mediastinal B-Cell...